公开(公告)号：US12203938B2

公开(公告)日：2025-01-21

申请号：US17548239

申请日：2021-12-10

Applicant: ARK Diagnostics, Inc.

Inventor： Johnny Jose Valdez ,  Byung Sook Moon ,  Ki Chung ,  Alejandro A. Orozco

IPC: G01N33/58 ,  C07D207/26 ,  C07K16/44 ,  G01N33/94

Abstract: Methods, compositions and kits are disclosed directed at levetiracetam derivatives, immunogens, signal generating moieties, antibodies that bind levetiracetam and immunoassays for detection of levetiracetam.

公开(公告)号：US12202836B2

公开(公告)日：2025-01-21

申请号：US18342977

申请日：2023-06-28

Applicant: Pfizer Inc.

Inventor： John David Trzupek ,  Katherine Lin Lee ,  Mark Edward Bunnage ,  Seungil Han ,  David Hepworth ,  Frank Eldridge Lovering ,  John Paul Mathias ,  Nikolaos Papaioannou ,  Betsy Susan Pierce ,  Joseph Walter Strohbach ,  Stephen Wayne Wright ,  Christoph Wolfgang Zapf ,  Lori Krim Gavrin ,  Arthur Lee ,  David Randolph Anderson ,  Kevin Joseph Curran ,  Christoph Martin Dehnhardt ,  Eddine Saiah ,  Joel Adam Goldberg ,  Xiaolun Wang ,  Horng-Chih Huang ,  Richard Vargas ,  Michael Dennis Lowe ,  Akshay Patny

IPC: C07D491/056 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  C07C69/94 ,  C07D207/08 ,  C07D207/26 ,  C07D207/267 ,  C07D207/273 ,  C07D209/52 ,  C07D215/48 ,  C07D217/02 ,  C07D217/22 ,  C07D217/24 ,  C07D239/86 ,  C07D239/88 ,  C07D263/24 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D413/12 ,  C07D417/12 ,  C07D487/04 ,  C07D498/04 ,  C07F7/18

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, as defined in the specification. In an embodiment, a pharmaceutical composition can be in a liquid dosage form and can comprise a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof as an adjuvant and a therapeutic agent. In another embodiment, a method of adjuvant treating a disorder or condition can comprising administering the pharmaceutical composition to a patient.

公开(公告)号：US20240398757A1

公开(公告)日：2024-12-05

申请号：US18292989

申请日：2022-08-03

Applicant: COCRYSTAL PHARMA, INC.

Inventor： Irina C. Jacobson

IPC: A61K31/4015 ,  A61K31/45 ,  A61K31/454 ,  C07D207/26 ,  C07D211/76 ,  C07D401/12

Abstract: Provided are compounds of Formula (I), Formula (Ia), Formula (Ib), and their use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sample or patient, of reducing the amount of noroviruses or coronaviruses in a biological sample or patient, and of treating norovirus and coronavirus in a patient, comprising administering to said biological sample or patient a safe and effective amount of a compound of Formula (I), Formula (Ia), Formula (Ib), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11840497B2

公开(公告)日：2023-12-12

申请号：US17249171

申请日：2021-02-22

Applicant: PTC Therapeutics, Inc.

Inventor： Orion D. Jankowski ,  Kieron E. Wesson ,  Paul Mollard ,  William D. Shrader

IPC: C07C235/80 ,  C07C235/32 ,  C07C235/78 ,  C07C317/28 ,  C07D207/27 ,  C07D211/46 ,  C07D213/40 ,  C07D233/61 ,  C07D295/13 ,  C07D295/192 ,  C07D265/30 ,  C07D311/66 ,  C07D207/26 ,  C07D213/50 ,  C07D295/116 ,  C07D295/185 ,  A61P21/00 ,  A61P25/00 ,  A61P25/16 ,  A61P27/00 ,  C07D213/51

CPC classification number: C07C235/80 ,  A61P21/00 ,  A61P25/00 ,  A61P25/16 ,  A61P27/00 ,  C07C235/32 ,  C07C235/78 ,  C07C317/28 ,  C07D207/26 ,  C07D207/27 ,  C07D211/46 ,  C07D213/40 ,  C07D213/51 ,  C07D233/61 ,  C07D265/30 ,  C07D295/116 ,  C07D295/13 ,  C07D295/185 ,  C07D295/192 ,  C07D311/66 ,  C07C2601/02 ,  C07C2601/16

Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.

公开(公告)号：US11702424B2

公开(公告)日：2023-07-18

申请号：US16996117

申请日：2020-08-18

Applicant: Pfizer Inc.

Inventor： John David Trzupek ,  Katherine Lin Lee ,  Mark Edward Bunnage ,  Seungil Han ,  David Hepworth ,  Frank Eldridge Lovering ,  John Paul Mathias ,  Nikolaos Papaioannou ,  Betsy Susan Pierce ,  Joseph Walter Strohbach ,  Stephen Wayne Wright ,  Christoph Wolfgang Zapf ,  Lori Krim Gavrin ,  Arthur Lee ,  David Randolph Anderson ,  Kevin Joseph Curran ,  Christoph Martin Dehnhardt ,  Eddine Saiah ,  Joel Adam Goldberg ,  Xiaolun Wang ,  Horng-Chih Huang ,  Richard Vargas ,  Michael Dennis Lowe ,  Akshay Patny

IPC: C07D491/056 ,  C07F7/18 ,  C07D401/14 ,  C07D405/14 ,  C07D217/02 ,  C07D217/22 ,  C07D217/24 ,  C07D239/86 ,  C07D239/88 ,  C07D263/24 ,  C07D207/273 ,  C07D498/04 ,  C07D209/52 ,  A61K31/4015 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/517 ,  A61K31/5377 ,  C07C69/94 ,  A61K31/541 ,  A61K45/06 ,  C07D207/26 ,  C07D215/48 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/14 ,  C07D413/12 ,  C07D417/12 ,  C07D487/04 ,  A61K31/40 ,  C07D207/08 ,  C07D207/267

CPC classification number: C07D491/056 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/517 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/06 ,  C07C69/94 ,  C07D207/08 ,  C07D207/26 ,  C07D207/267 ,  C07D207/273 ,  C07D209/52 ,  C07D215/48 ,  C07D217/02 ,  C07D217/22 ,  C07D217/24 ,  C07D239/86 ,  C07D239/88 ,  C07D263/24 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D413/12 ,  C07D417/12 ,  C07D487/04 ,  C07D498/04 ,  C07F7/1804

Abstract: Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia,




as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

公开(公告)号：US20230192663A1

公开(公告)日：2023-06-22

申请号：US18168803

申请日：2023-02-14

Applicant: Pardes Biosciences, Inc.

Inventor： Lee D. Arnold ,  Andy Jennings ,  Walter Keung

IPC: C07D403/12 ,  C07D401/12 ,  C07D207/26 ,  C07D417/14 ,  C07D403/14 ,  C07D471/04 ,  C07D401/14

CPC classification number: C07D403/12 ,  C07D401/12 ,  C07D207/26 ,  C07D417/14 ,  C07D403/14 ,  C07D471/04 ,  C07D401/14

Abstract: The disclosure provides compounds, such as compounds of Formula II, with warheads and their use in treating medical diseases or disorders, such as viral infections. Pharmaceutical compositions and methods of making various compounds with warheads are provided. The compounds are contemplated to inhibit proteases, such as the 3C, CL- or 3CL-like protease.

公开(公告)号：US11178873B2

公开(公告)日：2021-11-23

申请号：US15747180

申请日：2016-07-15

Applicant: FMC CORPORATION

Inventor： Andrew Duncan Satterfield ,  Thomas Martin Stevenson

IPC: A01N47/38 ,  C07D233/38 ,  C07D207/26 ,  C07D207/27 ,  C07D263/26

Abstract: Disclosed are compounds of Formula (1), including all stereoisomers, N-oxides, and salts thereof, (Formula (1)) wherein G, J, Q1, R4, Y2, Q2, R5 and Y1 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula (1) and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound or a composition of the invention.

公开(公告)号：US11066361B2

公开(公告)日：2021-07-20

申请号：US16732537

申请日：2020-01-02

Applicant: Cayman Chemical Company, Inc.

Inventor： Stephen Douglas Barrett ,  Fred Lawrence Ciske ,  Joseph Michael Colombo ,  Gregory William Endres ,  Bradlee David Germain ,  Andriy Kornilov ,  James Bernard Kramer ,  Adam Uzieblo ,  Kirk M. Maxey

IPC: C07D207/273 ,  C07D207/26 ,  C07D409/06 ,  A61K31/4025 ,  A61K31/4015 ,  A61L24/00 ,  A61L24/02 ,  A61L27/12 ,  A61L27/36 ,  A61L27/54 ,  A61L27/58

Abstract: Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

公开(公告)号：US10919863B2

公开(公告)日：2021-02-16

申请号：US16319957

申请日：2017-07-28

Applicant: Vectus Biosystems Limited

Inventor： Karen Annette Duggan

IPC: C07D239/26 ,  A61P11/00 ,  C07C39/15 ,  C07C215/54 ,  C07C233/11 ,  C07D207/408 ,  C07D213/56 ,  C07D237/08 ,  C07D261/14 ,  C07D263/44 ,  C07D277/30 ,  C07D401/10 ,  C07D403/10 ,  C07D333/24 ,  C07C233/07 ,  C07D231/56 ,  C07D235/26 ,  C07D235/06 ,  C07C59/52 ,  C07C275/42 ,  C07D213/73 ,  C07D277/68 ,  A61P11/06 ,  C07D231/12 ,  C07C211/29 ,  C07D207/38 ,  C07C255/00 ,  C07C271/28 ,  C07C217/48 ,  C07C261/04 ,  C07D241/12 ,  C07D309/10 ,  C07D233/78 ,  C07D261/08 ,  C07D209/48 ,  C07C237/20 ,  C07D207/327 ,  C07C237/22 ,  C07D307/54 ,  C07D249/18 ,  C07D209/34 ,  C07D263/38 ,  C07C307/10 ,  C07D207/26 ,  C07D207/444 ,  C07C235/34 ,  C07C311/03 ,  C07C311/08 ,  C07C239/20 ,  C07C235/78 ,  C07D209/18 ,  C07D263/58 ,  C07D215/14 ,  C07D207/40 ,  A61K45/06

Abstract: The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.

公开(公告)号：US10906875B2

公开(公告)日：2021-02-02

申请号：US16427629

申请日：2019-05-31

Applicant: California Institute of Technology

Inventor： Brian M. Stoltz ,  Scott C. Virgil ,  David E. White ,  Taiga Yurino ,  Yiyang Liu ,  Douglas C. Behenna ,  Douglas Duquette ,  Christian Eidamshaus

IPC: C07D211/78 ,  C07D211/16 ,  C07D211/18 ,  C07D211/22 ,  C07D211/34 ,  C07D211/38 ,  C07D211/60 ,  C07D211/76 ,  C07D211/88 ,  C07D211/90 ,  C07D211/94 ,  C07D211/96 ,  C07D207/06 ,  C07D207/08 ,  C07D207/10 ,  C07D201/16 ,  C07D207/26 ,  C07D207/263 ,  C07D207/267 ,  C07D207/27 ,  C07D207/273 ,  C07D207/277 ,  C07D207/46 ,  C07D223/04 ,  C07D223/10 ,  C07D241/04 ,  C07D241/08 ,  C07D241/52 ,  C07D265/30 ,  C07D265/32 ,  C07D309/04 ,  C07D309/30 ,  C07D207/16

Abstract: The invention provides heterocyclic compounds with quaternary centers and methods of preparing compounds. Methods include the method for the preparation of a compound of Formula (II): comprising treating a compound of Formula (I): with a transition metal catalyst and under alkylation conditions as valence and stability permit.